Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

IBD: full-pipeline trial registry

2 of 6 indexed IBD trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

IBD: 6 US clinical trials tracked, 2 recruiting.

IBD is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 2 of these trials.

Enrollment posture brief

Registry condition ibd

OPEN 2 | RECR 33% | LATE 1 | EARLY 1 | RANK #2866 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%IBD (this)33%
Open-enrollment share among volume-matched conditions near IBD

IBD lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for IBD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. IBD is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates IBD research.

    Children's Hospital Medical Center, Cincinnati accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical IBD enrolment sits around 120 participants.

    Median target enrolment is 120 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. IBD splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Named interventions

Most-linked intervention names on IBD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

SMART-IBD Behavioral
2 trials
TD-1473 - Dose C Drug
1 trials
TD-1473 - Dose B Drug
1 trials
TD-1473 - Dose A Drug
1 trials
Group 1: Placebo Drug
1 trials
Group 3: ustekinumab approximately 6 mg/kg Drug
1 trials
Group 2 ustekinumab 130 mg Drug
1 trials
Breath Test Other
1 trials

US sites by state

Facility locations filed on IBD trials. A trial with sites in several states counts in each.

Ohio 3 trials
Connecticut 2 trials
California 2 trials
Kentucky 1 trials
Illinois 1 trials
Iowa 1 trials
Georgia 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this IBD page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IBD condition card totals 6 registered trials; most-linked intervention SMART-IBD; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.